1065 related articles for article (PubMed ID: 15888152)
21. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
Torii H; Sato N; Yoshinari T; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
[TBL] [Abstract][Full Text] [Related]
22. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
23. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.
Reich K; Griffiths CE
Arch Dermatol Res; 2008 Nov; 300(10):537-44. PubMed ID: 18784934
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
30. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
31. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
[TBL] [Abstract][Full Text] [Related]
32. Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks.
Sivanesan SP; Gattu S; Hong J; Chavez-Frazier A; Bandow GD; Malick F; Kricorian G; Koo J
J Am Acad Dermatol; 2009 Nov; 61(5):793-8. PubMed ID: 19766350
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
Ho SG; Yeung CK; Chan HH
Clin Exp Dermatol; 2010 Oct; 35(7):717-22. PubMed ID: 19925489
[TBL] [Abstract][Full Text] [Related]
34. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
[TBL] [Abstract][Full Text] [Related]
35. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
Feagan BG; Reinisch W; Rutgeerts P; Sandborn WJ; Yan S; Eisenberg D; Bala M; Johanns J; Olson A; Hanauer SB
Am J Gastroenterol; 2007 Apr; 102(4):794-802. PubMed ID: 17324131
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
37. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
38. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
Kavanaugh A; Antoni C; Krueger GG; Yan S; Bala M; Dooley LT; Beutler A; Guzzo C; Gladman D
Ann Rheum Dis; 2006 Apr; 65(4):471-7. PubMed ID: 16096330
[TBL] [Abstract][Full Text] [Related]
39. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
40. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
Rich P; Griffiths CE; Reich K; Nestle FO; Scher RK; Li S; Xu S; Hsu MC; Guzzo C
J Am Acad Dermatol; 2008 Feb; 58(2):224-31. PubMed ID: 18083272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
